Tolanz 5/Tolanz 10

Olanzapine

Management of schizophrenia & treatment of moderate to severe mania associated w/ bipolar disorder.

Schizophrenia Initially 10 mg daily. Acute manic episodes Initially 10-15 mg daily as monotherapy or 10 mg in combination therapy; may be adjusted in dosage of 5 mg subsequently at intervals of not <24 hr if necessary w/in the range of 5-20 mg daily. Prevention of recurrence 10 mg daily. Renal &/or moderate hepatic impairment 5 mg daily. Female, elderly or non-smoking patient Lower initial dose of 5 mg daily should be escalated gradually.

May be taken with or without food: Place tab in the mouth & allow to dissolve completely then, swallow w/ saliva. Alternatively, disperse in a full glass of water or other beverages (orange juice/apple juice/milk/coffee) immediately prior administration.

Hypersensitivity. Known risk for narrow-angle glaucoma.

Neuroleptic malignant syndrome. Increased risk for stroke in elderly patients w/ dementia-related psychosis. Monitor glucose control regularly. Patients w/ risk factors for DM (eg, obesity, family history of diabetes); hyperglycemia, prostatic hypertrophy, paralytic ileus & related conditions; history of seizures or risk factors that may lower seizure threshold. Avoid abrupt w/drawal. Associated psychosis in patients w/ Parkinson's disease. Elevated AST &/or ALT in patients w/ hepatic impairment, preexisting conditions associated w/ limited hepatic functional reserve & those being treated w/ potentially hepatotoxic drugs. Low leukocyte &/or neutrophil counts in patients w/ history of drug-induced bone marrow depression/toxicity, bone marrow depression caused by concomitant illness, radiation or chemotherapy, hypereosinophilic conditions, myeloproliferative disease & those receiving drugs known to cause neutropenia. Concomitant use w/ other centrally-acting drugs & alcohol, direct & indirect dopamine agonists, other antipsychotics. Measure BP periodically in patients >65 yr. May impair ability to drive & use machines. Pregnancy & lactation.

Somnolence, wt gain; hyperprolactinemia. Increased appetite, dizziness, elevated plasma glucose, triglyceride & liver enzyme values, eosinophilia, edema, orthostatic hypotension, mild transient antimuscarinic effects eg, constipation & dry mouth.

May enhance central effects of other CNS depressants including alcohol. May antagonize actions of dopaminergics. Neutropenia may occur w/ valproate. Other drugs known to prolong QT interval. May affect plasma conc by CYP1A2 inhibitors, inducers or substrates. Inhibited metabolism w/ fluvoxamine. Increased clearance w/ tobacco smoking & carbamazepine.

Antipsychotics

N05AH03 - olanzapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics

Rx